Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C RPT193 · 1 trial · 1 indication
Amount (in mass equivalents of parent drug) of radioactive drug excreted as TRA in urine and feces
Percent (%) of radioactive drug excreted as TRA in urine and feces
Percent (%) of each drug-related material (parent and each metabolite) in whole blood, plasma, urine and feces
Calculation of area under the curve (AUC) in plasma and urine
| Arm | Type | Description |
|---|---|---|
| 14C RPT193 400 mg | EXPERIMENTAL | Radiolabelled RPT193 |
| Name | Type | Description |
|---|---|---|
| 14C RPT193 | DRUG | Radiolabelled RPT193 |
Inclusion Criteria: * Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to dosing * Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at the screening Exclusion Criteria: * Is mentally or legally incapacitated or has significant emotional pro...
14C RPT193 is an investigational small molecule being developed by RAPT Therapeutics, Inc. (RAPT). It is currently in Phase 1 clinical development. The drug has been studied in a completed clinical trial involving healthy male subjects.
14C RPT193 is being studied for use in healthy male subjects. The completed Phase 1 trial, NCT06087978, enrolled 7 healthy adult male participants in the United States. The study was uncontrolled and did not use randomization or blinding.
14C RPT193 is being developed by RAPT Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol RAPT. The company conducted a Phase 1 clinical trial of the drug in healthy male subjects.
14C RPT193 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. One Phase 1 trial, NCT06087978, has been completed, and no active trials are currently listed.
14C RPT193 has been studied in one clinical trial, NCT06087978, titled "Study of RPT193 in Healthy Adult Male Subjects." This Phase 1 trial was completed in the United States and enrolled 7 healthy male participants aged 19 years and older.